Northern Trust Corp Grows Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Northern Trust Corp increased its holdings in Jazz Pharmaceuticals PLC by 0.8% in the first quarter, currently owning approximately 0.85% of the company worth $65.2 million.
• Several large investors have also adjusted their positions, with 89.14% of Jazz Pharmaceuticals' stock now held by hedge funds and institutional investors.
• Jazz Pharmaceuticals received mixed ratings from analysts, with target prices ranging from $147.00 to $202.00 and an overall average rating of "Moderate Buy."

Northern Trust Corp raised its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 0.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 525,163 shares of the specialty pharmaceutical company's stock after purchasing an additional 3,967 shares during the period. Northern Trust Corp owned 0.85% of Jazz Pharmaceuticals worth $65,199,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hurley Capital LLC acquired a new position in Jazz Pharmaceuticals during the first quarter worth approximately $25,000. Elequin Capital LP increased its position in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 183 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 85.6% during the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after purchasing an additional 119 shares during the period. Picton Mahoney Asset Management grew its holdings in shares of Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock worth $34,000 after purchasing an additional 269 shares during the period. Finally, Spire Wealth Management grew its holdings in shares of Jazz Pharmaceuticals by 137.6% during the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after purchasing an additional 161 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on JAZZ shares. The Goldman Sachs Group boosted their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a report on Friday. Needham & Company LLC reiterated a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday. Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 target price for the company. Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Finally, Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday. Fourteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $178.67.

Jazz Pharmaceuticals Stock Up 1.3%

Shares of Jazz Pharmaceuticals stock traded up $1.62 on Friday, hitting $127.75. 675,563 shares of the company's stock traded hands, compared to its average volume of 950,533. The stock has a market cap of $7.75 billion, a P/E ratio of -18.98, a PEG ratio of 7.84 and a beta of 0.34. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The firm's 50-day moving average is $114.07 and its 200 day moving average is $117.25. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares in the company, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.